These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32086295)

  • 1. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
    Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
    AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.
    Singh AP; Shah DK
    Drug Metab Dispos; 2017 Nov; 45(11):1120-1132. PubMed ID: 28821484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
    Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
    AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
    Singh AP; Shah DK
    J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
    Chang HP; Cheung YK; Liu S; Shah DK
    Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
    Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors.
    Menezes B; Linderman JJ; Thurber GM
    Drug Metab Dispos; 2022 Jan; 50(1):8-16. PubMed ID: 34649966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
    Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
    J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
    Vasalou C; Proia TA; Kazlauskas L; Przybyla A; Sung M; Mamidi S; Maratea K; Griffin M; Sargeant R; Urosevic J; Rosenbaum AI; Yuan J; Aluri KC; Ramsden D; Hariparsad N; Jones RDO; Mettetal JT
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):994-1005. PubMed ID: 38532525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.